← Search & browse all drugs

vaccinia immunoglobulin

J06BB07

Forms & Strengths

Solution for injection: 50,000 units/mL in 5 mL vials

Adult Dosing

Treatment of eczema vaccinatum: 100,000 units/kg IM as soon as possible after symptom onset
Treatment of progressive vaccinia: 100,000 units/kg IM, repeated every 2 to 3 days until healing begins
Treatment of severe generalized vaccinia: 100,000 units/kg IM
Treatment of vaccinia infections in ocular keratitis: 100,000 units/kg IM

Pediatric Dosing

Treatment of eczema vaccinatum: 100,000 units/kg IM as soon as possible
Treatment of progressive vaccinia: 100,000 units/kg IM, repeated every 2 to 3 days until healing begins
Treatment of severe generalized vaccinia: 100,000 units/kg IM
Dosing is weight-based and identical to adult weight-based dosing

Indications

Treatment of eczema vaccinatum
Treatment of progressive vaccinia (vaccinia necrosum)
Treatment of severe generalized vaccinia
Treatment of aberrant infections induced by vaccinia virus in skin (except isolated ocular keratitis)

Mechanism of Action

Provides passive immunity by supplying neutralizing antibodies against the vaccinia virus
Mitigates replication and spread of vaccinia virus manifestations resulting from smallpox vaccination complications

Contraindications

History of severe hypersensitivity reaction to human immunoglobulin or any component of the formulation
IgA deficiency with antibodies to IgA and a history of hypersensitivity

Adverse Reactions

Pain, tenderness, and erythema at the injection site
Hypersensitivity reactions including anaphylaxis
Fever, chills, and malaise
Headache and dizziness
Nausea and vomiting

Drug Interactions

May interfere with the immune response to live virus vaccines (e.g., measles, mumps, rubella, varicella)
Defer live virus vaccination for 3 months or more after administration of vaccinia immune globulin

Curated Content: Needs Vetting Before Put to Clinical Use